SCHEMBL12301701

SCHEMBL12301701

CC(=O)OC[C@H]1O[C@@H](CN)[C@H](OC(C)=O)[C@@H]1OC(C)=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 13/20 0.57
▸ CA12 O43570 12/20 0.57
▸ CA1 P00915 12/20 0.57
▸ CA9 Q16790 8/20 0.57
▸ THRB P10828 2/20 0.56
▸ CYP2D6 P10635 1/20 0.56
▸ HSD17B10 Q99714 1/20 0.56
▸ TSHR P16473 1/20 0.55
▸ NR3C1 P04150 1/20 0.55
▸ FYN P06241 1/20 0.55
▸ ADRA2A P08913 1/20 0.55
▸ ADORA3 P0DMS8 1/20 0.55
▸ ADRA2B P18089 1/20 0.55
▸ DRD4 P21917 1/20 0.55
▸ DRD3 P35462 1/20 0.55
▸ CA4 P22748 6/20 0.50
▸ CA5A P35218 6/20 0.50
▸ CA7 P43166 6/20 0.50
▸ CA5B Q9Y2D0 6/20 0.50
▸ LMNA P02545 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11170651 0.91 THRB (0.64) CA2CA12CA1CA9THRB
SCHEMBL11167401 0.91 THRB (0.64) CA2CA12CA1CA9THRB
SCHEMBL5948793 0.91 THRB (0.64) CA2CA12CA1CA9THRB
SCHEMBL17366216 0.89 CYP2D6 (0.67) CA2CA12CA1CA9THRB
SCHEMBL26224815 0.89 CYP2D6 (0.67) CA2CA12CA1CA9THRB
SCHEMBL16392999 0.87 LMNA (0.56) CA2CA12CA1CA9THRB
SCHEMBL13191366 0.85 CA2 (0.56) CA2CA12CA1CA9THRB
SCHEMBL18452481 0.83 CA12 (0.58) CA2CA12CA1CA9THRB
SCHEMBL25920024 0.83 CA2 (0.57) CA2CA12CA1CA9THRB
SCHEMBL12123791 0.83 CA2 (0.57) CA2CA12CA1CA9THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237785-A1 SPATIALLY-DEFINED MACROCYCLIC COMPOUNDS USEFUL FOR DRUG DISCOVERY MALLINCKRODT CARRIBEAN, INC. 2011-09-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237785-A1 SPATIALLY-DEFINED MACROCYCLIC COMPOUNDS USEFUL FOR DRUG DISCOVERY MLNR, GIPR, CCKAR CA2 3214/4885CA12 3195/4885CA1 2880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback